Trials / Unknown
UnknownNCT04140201
Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients
Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Alaa Hassan ElBaz · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The investigator study evaluate the effect of different lipid lowering agents on the progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic patients
Detailed description
The investigator study compare the effect of lipid lowering agent on the enhancement of visual acuity and on reduction of macular edema in patients with diabetic retinopathy and also compare their effect on reduction of cardiovascular risk on diabetic patients via assessment of ASCVD risk score
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Simvastatin 40mg | Drugs that lower lipid level |
| DRUG | Fenofibrate 200mg | Drugs that lower lipid levels |
| DRUG | Omega 3 fatty acid | Drugs that lower lipid levels |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-06-01
- Completion
- 2020-08-01
- First posted
- 2019-10-25
- Last updated
- 2020-01-18
Source: ClinicalTrials.gov record NCT04140201. Inclusion in this directory is not an endorsement.